基于计算机的多星仪电谱仪程脑电图数据
2019年11月13日
13.9K 次观看
该协议提供了一个开源的、编译的MATLAB程序，用于为脑电图数据生成多发图谱图。
该协议非常重要，因为它使用户能够在没有事先信号处理知识的情况下开发可定制的多分镜程频谱图。该程序的主要技术优势是程序的用户友好设计，以及使用没有 MATLAB 许可的计算机创建多数据谱谱的能力。电极植入手术后7至10天，配置数据采集系统以毫伏为单位记录所有信号，并获取所需实验持续时间的EEG记录。
使用适当的数据采集仪器和软件放大未经过滤的 EEG 信号并数字化。然后让两个不同的个体在适当的睡眠评分软件程序中，对数字 EEG、蓝色轨迹和 EMG、黑色轨迹、记录作为觉醒、REM 睡眠或非 REM 睡眠的每个 10 秒的 bin 进行独立评分。下载已编译的多塔谱谱计划。
对于频谱图计算，以 EDF 或 CSV 文件格式获取原始、未处理的 EEG 数据，然后将文件放在与编译的程序文件相同的位置，然后启动频谱图程序。按照弹出提示操作，然后选择适当的文件格式。输入整个 EEG 文件名，然后选择频谱图计算的参数。
输入光谱图和 EEG 的标题。然后，单击"文件"和"保存"以以所需的文件格式保存生成的光谱图和 EEG 跟踪。此图显示了在觉醒、非 REM 睡眠和 REM 睡眠期间皮质 EEG 的代表性相似性和差异。
此催眠图用于根据对 EEG 和 EMG 记录的评估绘制睡眠和觉醒状态的时间组织。与离散的催眠图相比，光谱图可用于说明 EEG 频率和功率作为时间函数的极动态变化，并突出显示唤醒和 REM 睡眠期间的皮质 EEG 信号之间的相似性。这些多分子光谱图在系统化盐水、吗啡、丁丙诺啡或芬太尼后，每组总结四个小时的脑电图记录。
此图显示了使用光谱图来可视化不同阿片剂对皮质脑电图功率的影响。盐水条件中的慢波活性被吗啡和丁丙诺啡消除。芬太尼管理后，可以观察到慢波增量功率。
光谱图所图所示的 EEG 变化可以进一步量化，并表示为每半频率的平均主导光谱功率。例如，如图所示，平均特定 EEG 频段内的光谱功率表明，在 0.5 至 4 赫兹的频率范围内，盐水处理的 EEG 功率比丁丙诺啡高得多。长期植入脑电图和EG电极的小鼠在几个月内保持健康，从而对药物-药物相互作用和慢性药物给药进行新的研究。
此外，这些技术可以为开发阿片剂引起的呼吸抑郁症的化学对策提供新的见解。
概述
本协议描述了一个用于生成多重窗口谱图以分析脑电图（EEG）数据的开源MATLAB程序。它使用户能够创建可定制的谱图，而无需具备信号处理的先前知识。
关键研究组成部分
科学领域
- 电生理学
- 信号处理
- 神经科学
背景
- 脑电图（EEG）用于监测大脑活动。
- 多重窗口技术增强了EEG数据的谱分析。
- 了解各种物质对EEG动力学的影响至关重要。
- 常见的阿片类药物对皮层EEG模式显示出显著影响。
研究目的
- 提供一种用户友好的方法来生成多重窗口谱图。
- 分析EEG频率和功率的动态变化。
- 可视化不同阿片类药物对皮层EEG功率的影响。
使用的方法
- 该研究采用编译的MATLAB程序进行谱图计算。
- 生物模型涉及在小鼠中长期植入EEG和EMG电极。
- EEG数据必须在手术后约7-10天以毫伏为单位收集。
- 参与者使用适当的软件对EEG数据进行评分，以分类睡眠状态。
- 重要文件必须为EDF或CSV格式，以便与程序兼容。
主要结果
- 该程序成功地可视化了EEG动力学，并比较了各种阿片类药物的影响。
- 在给予吗啡和丁丙诺啡后观察到显著的谱功率变化。
- 在0.5到4 Hz频率范围内，盐水治疗的EEG功率水平比丁丙诺啡高。
- 长期电极植入促进了对物质影响的长期研究。
结论
- 本研究展示了MATLAB程序在EEG数据分析中的实用性。
- 程序的开源性质使其在神经科学研究中更具可访问性。
- 获得的见解可能阐明阿片类药物对大脑活动的影响，有助于与药物相关的研究。
常见问题
使用MATLAB程序的优点是什么？
该程序是开源的且用户友好，不需要先前的信号处理知识，使其适用于各种研究应用。
EEG数据如何收集？
EEG数据从植入电极的小鼠中收集，通常在手术后7-10天，在所需的实验期间以毫伏为单位记录信号。
使用这种方法可以获得哪些类型的数据？
用户可以获得详细的谱图，说明EEG频率和功率动态，允许研究物质对大脑活动的影响。
该方法可以适应不同的研究需求吗？
是的，该程序允许自定义谱图参数，使研究人员能够根据其具体实验设计进行定制分析。
该协议是否有任何限制？
主要的限制是它需要一些管理文件格式的熟悉度和基本的EEG数据解释理解。
对EEG数据进行什么类型的评分？
EEG数据的每10秒钟的分段都使用专门的软件独立评分为清醒、快速眼动睡眠或非快速眼动睡眠。
Executive Industry Relevance
This open-source multitaper spectrogram program enables biopharma researchers to visualize and quantify EEG dynamics without requiring MATLAB licensing or signal processing expertise. By providing a user-friendly tool for analyzing sleep-wake states and drug-induced alterations in cortical EEG power, the method supports target validation and mechanistic de-risking in neuroscience drug discovery. The program’s ability to unmask differential opiate effects on EEG frequency and power offers predictive value for assessing compound activity across therapeutic classes.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by visualizing drug-induced changes in EEG power spectra across frequency bands.
- Operational Value: Supports biological de-risking through quantifiable, reproducible EEG readouts that clarify target engagement and pathway modulation.
- Predictive Value: Facilitates portfolio triage by identifying compounds with distinct electrophysiological signatures, such as differential effects of morphine, buprenorphine, and fentanyl on slow-wave and spindle activity.
Screening & Assay Development
- Assay Readiness: Prepares validated biological systems (chronic EEG-implanted mice) for downstream compound evaluation by establishing baseline and drug-responsive EEG signatures.
- Quantitative Outputs: Generates measurable spectral power averages in defined frequency ranges (e.g., 0.5–4 Hz, 8–9 Hz) enabling standardized comparison across treatment groups.
- Platform Reuse: The open-source, Windows-compatible program allows scalable application across labs without licensing barriers, supporting assay standardization and cross-study comparability.
Translational & Preclinical Research
- Disease Relevance: Models sleep-wake disruption and opiate-induced EEG alterations, providing a disease-relevant system for studying CNS-active compounds.
- Translational Continuity: Enables longitudinal studies due to chronic electrode stability, supporting risk-adjusted advancement decisions from discovery through preclinical validation.
- Mechanistic De-risking: Highlights substance-specific EEG patterns (e.g., fentanyl-induced 3 Hz and 7 Hz power bands) that aid in distinguishing mechanism of action and off-target effects.
Pipeline & Workflow Integration
The method fits within the discovery continuum from hypothesis testing to lead identification, offering EEG-based functional readouts that bridge in vivo phenotyping and mechanistic insight.
- Discovery Biology: Supports hypothesis testing by visualizing how compounds alter cortical EEG dynamics across sleep and wake states, clarifying neurophysiological targets.
- Screening: Delivers assay-ready, quantitative EEG outputs (e.g., average dominant spectral power) that enable reliable compound evaluation and hit confirmation.
- Analytics: Provides spectral analysis capabilities (multitaper spectrograms, frequency band power quantification) that allow teams to compare conditions and detect subtle, dynamic changes in brain activity.
- Translational Research: Connects to preclinical continuity through chronic EEG monitoring in freely moving mice, enabling assessment of sustained drug effects and tolerance development.
- Enterprise Reuse: Framed as a reusable, open-access capability rather than a single-use technique, the program supports standardization across sites and projects in neuropsychopharmacology research.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in target validation by reducing mechanistic ambiguity through objective, frequency-resolved EEG phenotyping.
- Operational Value: Enhances standardization and reproducibility via a consistent, user-friendly platform for spectral analysis across laboratories.
- Strategic Value: Improves go/no-go decisions by enabling early detection of neuroactive compound effects, reducing late-stage biological risk in CNS drug development.
- Portfolio Impact: Supports risk-adjusted prioritization by identifying compounds with favorable EEG profiles, such as those preserving or modulating specific frequency bands linked to therapeutic intent.
Implementation Considerations
- Requires basic proficiency in EEG data acquisition, file management (EDF/CSV), and sleep state scoring using validated software.
- Needs instrumentation capable of amplifying and digitizing unfiltered EEG signals in millivolts from chronically implanted electrodes.
- Demands cross-team standardization in EEG preprocessing, scoring protocols, and spectrogram parameter selection to ensure reproducibility.
- Involves adaptation considerations when applying the model to other species, strains, or disease models beyond opioid-naïve C57BL/6J mice.
- Practical limitation: Macintosh users require a MATLAB license to run the program, restricting access for some teams despite the open-source Windows version.
Biopharma FAQs
Why does multitaper spectrogram analysis matter for target validation in CNS drug discovery?
Multitaper spectrogram analysis enables objective visualization and quantification of drug-induced changes in EEG power across frequency bands, such as delta (1–3 Hz) and spindle (8–9 Hz) activity. This provides mechanistic insight into target engagement and pathway modulation, reducing ambiguity in early target validation. By revealing differential effects of compounds like morphine, buprenorphine, and fentanyl, it supports hypothesis-driven prioritization of CNS-active molecules.
How does isolating independent variables (e.g., drug type, dose) fit into the discovery pipeline using this EEG method?
The method allows researchers to isolate the effects of specific compounds (e.g., saline vs. morphine) on EEG spectra by holding constant variables such as strain, electrode placement, and recording duration. This controlled comparison enables clear attribution of spectral changes to the independent variable, supporting reliable structure-activity relationship (SAR) assessments. Such isolation is critical for de-risking targets early in the discovery pipeline before advancing to complex phenotypic screens.
What quantitative dependent variable measurements does the spectrogram program enable for compound evaluation?
The program enables measurement of average dominant spectral power within defined EEG frequency bands (e.g., 0.5–4 Hz, 8–9 Hz), providing a quantitative dependent variable for comparing treatment groups. These measurements allow researchers to detect significant shifts in cortical EEG power following compound administration, such as reduced slow-wave activity after morphine or buprenorphine. Such quantifiable outputs support hit confirmation and lead optimization by offering reproducible, dose-responsive biomarkers of CNS activity.
Why do replication requirements (e.g., dual independent scoring) matter for cross-functional collaboration in EEG studies?
Independent scoring of EEG, EMG, and hypnogram data by two individuals reduces observer bias and increases reliability of sleep-wake state classification, which underpins accurate spectrogram interpretation. This replication ensures that observed EEG changes are attributable to drug effects rather than scoring variability, enhancing data integrity across teams. Standardized, reproducible scoring supports cross-functional trust between biology, analytics, and translational teams in multi-site preclinical programs.
What statistical analysis capabilities are required before implementing this spectrogram method in a drug discovery workflow?
Before implementation, teams should establish capability for comparing spectral power across groups using appropriate statistical tests (e.g., t-tests, ANOVA) on averaged frequency band power (e.g., 3 Hz, 7 Hz peaks post-fentanyl). The method requires preprocessing steps such as file format conversion (EDF/CSV) and baseline normalization to enable valid comparisons. Access to basic biostatistical support or software (e.g., GraphPad, Prism, R) is necessary to derive meaningful conclusions from spectrogram-generated data.
